For over four decades, HIV has been one of the deadliest pandemics in human history, claiming the lives of more than 44 million people since 1981. Until recently, a diagnosis meant a near-certain death sentence, particularly in underserved regions where access to treatment remains limited. However, the landscape has dramatically shifted.
Global progress has been staggering. Deaths from AIDS-related illnesses have fallen by 70% since their peak, and approximately 30 million people now live with HIV while being sustained on antiretroviral therapy (ART). These drugs have transformed the virus from a fatal condition into a manageable chronic illness. Even more groundbreaking, long-acting injectable medications are now available that provide up to six months of HIV prevention with a single dose, and the prospect of a functional vaccine is becoming increasingly realistic.
For the first time, eradicating HIV is not just a theoretical possibility, but a tangible goal within reach.
Yet, at this critical juncture, the very financial and political backing that fueled this success is under threat. Funding for global health programs—the same programs that have saved countless lives—are facing drastic cuts both internationally and domestically. This rollback in investment is particularly dangerous because the tools to defeat HIV exist; the only remaining obstacle is maintaining the will to deploy them effectively.
This isn’t just a matter of abstract statistics. Reduced funding will directly translate into lost lives, increased infections, and a resurgence of a disease that was once considered unstoppable. The coming months will see increased scrutiny of how HIV programs operate, from the role of pharmaceutical companies to the lived experiences of those affected.
The question before us is no longer if we can end HIV, but whether we will. The answer depends on sustained commitment, not abandonment.
This reporting is sponsored by Gilead Sciences, with full editorial control retained by Vox. This disclosure is important because pharmaceutical partnerships play a vital role in HIV research and treatment access, and transparency is essential to maintaining public trust.
